GIOTRIF in First Line Therapy of Advanced NSCLC With EGFR-mutations

N/ACompletedNCT02047903

Boehringer Ingelheim161 enrolled

Overview

This observational study will investigate the efficacy, safety, tolerability and symptom control of GIOTRIF (Afatinib) in daily routine first-line therapy in patients with locally advanced or metastatic NSCLC harboring EGFR-mutations. Eligible NSCLC patients, for whom the treating physician has decided to initiate treatment with GIOTRIF in first line according to the local label, will be followed up for approximately 24 months.

Study Design:

Study Type

OBSERVATIONAL

Enrollment

161

Conditions

Carcinoma, Non-Small-Cell Lung

Interventions

AfatinibDRUG

50, 40, 30 or 20 mg

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion criteria: * EGFR- tyrosine kinase inhibitor (TKI) naive patients with histologically confirmed locally advanced or metastatic NSCLC with activating EGFR-mutations * Age \>= 18 years * No diagnostic or therapeutic measures beyond routine clinical practice are required * Patients for whom the treating physician has decided to initiate treatment with GIOTRIF * Written informed consent prior inclusion Exclusion criteria: * Contraindication for Afatinib according to the Summary of Product characteristics * Participation in another clinical study until 30 days after end of treatment * Prior systemic chemotherapy (Neo-/adjuvant therapy is permitted) * Previous treatment with an EGFR-tyrosine kinase inhibitor * Patients not willing or not able to fill in quality of life questionnaires * Patients with missing or impaired legal capacity * Pregnancy

Locations (1)

Unnamed facility

Multiple Locations, Germany

Outcomes

Primary Outcomes

Progression Free Survival (PFS) Rate After 12 Months

The rate (probability) of being progression free after 12 months. PFS is defined as the time from first administration of the trial drug until objective tumor progression or death. The rate is the Kaplan-Meier estimated percent probability.

Time frame: After 12 months

Secondary Outcomes

Objective Response Rate (ORR)

Objective response rate is calculated as a percentage of participants with complete response (CR) or partial response (PR) (i.e CR+PR) as best unconfirmed response. Here CR and PR were determined by investigators by using RECIST/WHO/clinical evidence as investigators deemed appropriate.

Time frame: From the initial dose of study drug until end of the treatment period, up to 48 months.

Disease Control Rate (DCR)

Percentage of participants with controlled disease (CR + PR + stable disease (SD)) as best unconfirmed response. CR, PR and SD were determined by investigators by using RECIST/WHO/clinical evidence as investigators deemed appropriate

Time frame: From the initial dose of study drug until end of the treatment period, up to 48 months.

Progression Free Survival (PFS)

PFS was measured from start of therapy until progression or death, whichever came first. Progression was defined as the minimum of the first examination with progression and the date of progression documented by the treating physician. One day was added to the corresponding date. Patients without documented progression and not known to have died were censored at their date of last examination and one day was added. Median was derived by Kaplan Meier methods.

Time frame: From first administration of the trial drug until objective tumour progression or death, up to 48 months.

Percentage of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.

Symptom Control - Time to Worsening (Cough, Dyspnea and Pain)

Symptom control was evaluated for cough, dyspnea and pain. Time to deterioration was calculated from date of baseline European Organisation for Research and Treatment of Cancer (EORTC) questionnaire until date of the EORTC questionnaire, where the first deterioration was measured. Patients without deterioration were censored at their date of last answered EORTC questionnaire, where the corresponding scale is evaluable. Participants had to select one answer on a scale ranging from 1=Not at All to 4=Very Much for questions 1 to 28 and 31 to 43 and on scale ranging from 1=Very Bad to 7=Excellent for questions 29 and 30. Afterwards, these scale scores were linearly transformed such that all scales ranged from 0 to 100, where higher scores represented higher level of symptoms.

Time frame: Up to 48 months